Long wait times for chimeric antigen receptor T-cell (CAR-T) therapy for patients with diffuse large B-cell lymphoma (DLBCL) may lead to decreased effectiveness and increased complications, according to research published in JCO Clinical Cancer Informatics.

In the past few years, CAR-T therapy has been shown to be effective in select patients with relapsed or refractory DLBCL.

Researchers developed a health system-level discrete event simulation model to analyze the potential influence of wait times on CAR-T therapy outcomes in patients with relapsed or refractory DLBCL. Wait times, health status, and clinical progression served as variables in the model.


Continue Reading

Related Articles

The model was used to evaluate 9 scenarios with CAR-T therapy with wait times ranging from 1 to 9 months. Patients in this model were assumed to undergo chemotherapy while waiting to receive CAR-T therapy. The researchers simulated 10,000 patients receiving either CAR-T therapy or standard therapy and repeated the simulation 1000 times.

Baseline 1-year mortality with no wait time for CAR-T therapy was 34.0% in patients receiving CAR-T therapy compared with 75.1% in patients treated with chemotherapy. Increasing wait time from 1 to 9 months was found to increase predicted 1-year mortality from 36.1% to 76.3% in patients receiving CAR-T therapy.

Relative mortality rates increased between 6.2% and 124.5% for each additional month (up to 9) added to the baseline of no wait time. Mortality in patients receiving CAR-T therapy surpassed mortality in patients receiving chemotherapy when wait time exceeded 8 months.

In scenarios assessing outcomes with tisagenlecleucel CAR-T therapy and with no antylymphomic treatment during the wait, increased wait time was associated with increased mortality.

Even slight delays in CAR-T therapy administration could significantly hinder its efficacy and lead to complications. “Given the high cost of CAR-T therapy, it will be critical for clinicians and policymakers to develop wait time strategies that minimize delays in access to CAR-T therapy,” wrote the researchers.

Disclosures: Some authors have declared affiliations with the pharmaceutical industry. Please refer to the original study for a full list of disclosures.

Reference

1.     Tully S, Feng Z, Grindrod K, et al. Impact of increasing wait times on overall mortality of chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a discrete event simulation model [published online October 23, 2019]. doi:10.1200/CCI.19.00086

This article originally appeared on Hematology Advisor